Clinical Trials Browser

Not yet recruiting × Gemcitabine × Genitourinary × Clear all

NCT07332351 2026-03-13

TRIFECTA

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06972615 2026-02-17

Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06822010 2025-11-14

SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT06829823 2025-10-16

Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT07189793 2025-09-24

OHAI-NMIBC-01

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell

NCT07184021 2025-09-19

No Acronym

Phase 2 Not yet recruiting

Urinary Bladder Neoplasms

NCT07119996 2025-08-13

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Phase 1 Not yet recruiting

Urinary Bladder Neoplasms, Neoplasms

NCT07064863 2025-07-17

BCG-TIME

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Neoplasms

NCT06364904 2025-02-21

A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.

Phase 3 Not yet recruiting

Urinary Bladder Neoplasms

NCT06623162 2024-10-04

SASAN-SPARING

Phase 2 Not yet recruiting

Mibc

NCT06591650 2024-09-19

Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advanced or Metastatic Gallbladder Cancer

Phase 2 Not yet recruiting

GastrointestinalGenitourinary

Gallbladder Cancer Unresectable

NCT06327932 2024-03-25

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT06227065 2024-01-26

POLO

Phase 2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms